Article Correctness Is Author's Responsibility: Ozanimod Reduces Severe Relapses in Multiple Sclerosis More Than Interferon Beta-1a

The article below may contain offensive and/or incorrect content.

Treatments were evaluated for either 1 year (SUNBEAM) or 2 years (RADIANCE).